Jeff E. Knight is COO at Crinetics Pharmaceuticals, Inc. (CRNX). They have made 2 open-market trades across 1 company since 2022, most recently 2026-04-08.
CIK 0001881007
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CRNX | 105,289 | $8.9M |
Shares reported on the most recent Form 4, priced at the 2026-04-10 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CRNX | SELL · 10b5-1 | 2026-04-08 | 2026-04-10 | $40.10 | $3.4M | -0.2% | -6.7% | +113.4% |
| CRNX | SELL · 10b5-1 | 2026-03-16 | 2026-03-18 | $37.37 | $370K | -4.0% | +14.8% | -1.8% |
| CRNX | SELL · 10b5-1 | 2025-03-19 | 2025-03-21 | $34.19 | $477K | -9.3% | -12.9% | -12.9% |
| CRNX | SELL · 10b5-1 | 2024-11-22 | 2024-11-26 | $56.52 | $28K | -0.7% | -5.4% | -39.3% |
| CRNX | SELL · 10b5-1 | 2024-07-15 | 2024-07-17 | $55.00 | $1.5M | +1.4% | -3.6% | +7.6% |
| CRNX | SELL · 10b5-1 | 2024-06-26 | 2024-06-28 | $44.38 | $42K | +17.6% | +20.8% | +12.7% |
| CRNX | SELL | 2024-03-22 | 2024-03-26 | $44.38 | $1.5M | +6.5% | -3.0% | +4.7% |
| CRNX | SELL | 2022-07-26 | 2022-07-29 | $20.70 | $24K | +13.4% | +3.1% | -4.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.